Perform Cataract Surgery Midway Between Anti-VEGF Injections

Why It Matters

Mid‑cycle timing eliminates drug‑washout risk and simplifies care coordination, leading to safer cataract outcomes for patients on chronic anti‑VEGF therapy.

Key Takeaways

• Schedule cataract surgery at midpoint of anti‑VEGF injection interval
• Avoid injections on day of or adjacent to cataract operation
• No need to stabilize retinal disease before cataract extraction
• Coordinate retinal and cataract surgeons to reduce postoperative risks

Pulse Analysis

Anti‑VEGF agents such as ranibizumab and aflibercept have become the backbone of treatment for wet age‑related macular degeneration (AMD) and diabetic macular edema (DME). As the population ages, many patients requiring these injections also develop cataracts, creating a clinical overlap that demands careful scheduling. Historically, ophthalmologists have debated whether to pause anti‑VEGF therapy to “stabilize” the retina before lens removal, often leading to prolonged periods of sub‑optimal vision. Understanding the pharmacokinetics of these biologics—particularly their intra‑ocular half‑life—helps clarify why timing, rather than disease stabilization, is the critical factor.

In his May 2026 presentation, Dr. Steve Charles highlighted that performing cataract surgery at the midpoint of the injection interval avoids two pitfalls: drug wash‑out during the operative field and the confounding of postoperative inflammation with injection‑related adverse events. An injection given on the day of surgery may be flushed out by irrigation, rendering it ineffective, while an injection immediately before or after the procedure can mask early signs of toxic anterior segment syndrome or vasculitis. By aligning surgery with the trough of drug concentration, surgeons preserve the therapeutic effect of the prior injection and ensure the next dose arrives on schedule, maintaining disease control without interruption.

The practical upshot for clinics is a shift toward integrated care pathways. Retinal specialists must relay injection calendars to cataract surgeons, and vice‑versa, to lock in the optimal window. This coordination reduces the risk of postoperative complications, shortens visual recovery time, and eliminates the need for patients to endure years of delayed cataract removal while awaiting retinal stabilization. As more practices adopt this mid‑cycle protocol, outcomes data will likely confirm reduced complication rates and improved patient satisfaction, reinforcing the importance of interdisciplinary communication in modern ophthalmic care.